



## **Implanet files its *document de base* with the French *Autorité des marchés financiers* (AMF) ahead of its planned IPO on NYSE Euronext Paris**

**Paris, October 2, 2013** – Implanet, a medical technology company specialised in vertebral implants and knee surgery implants, announces the registration of its *document de base* with the French *Autorité des marchés financiers* (AMF) under number I13-045 dated October 1, 2013 ahead of its planned IPO on the NYSE Euronext market in Paris.

### **Extensive expertise in state-of-the-art orthopaedic implants**

In the space of just a few years, Implanet has developed well-known expertise in state-of-the-art orthopaedic implants and especially implants for knee surgery. Implanet recorded sales of €6.6 million in 2012 and now has the critical mass to continue rolling out Jazz, its next-generation spinal surgery implant.

### **Jazz, a next-generation spinal surgery implant**

Protected by four sets of international patents, Jazz caters to all of the procedures involved in vertebral fusion, a surgical technique used to restore spinal stability by fusing two adjacent vertebrae and fitting implants to stabilise the binding system. Thanks to the approvals it has already secured, i.e. the CE mark and FDA clearance in the United States, Jazz serves a market estimated to be worth over \$2 billion in two applications:

- repositioning the vertebral column with the utmost efficacy and restoring original curvature in severe cases of scoliosis and other major spine deformations, while restricting the use of pedicle screws; and
- replacing or securing pedicle screws for patients suffering from degenerative disc and bone diseases, which involve a high risk of instability associated with the mediocre quality of the bone tissue to which they are attached.

### **An implant offering tangible improvements by comparison with traditional implants**


Using Jazz implants in vertebral fusion provides better clinical results for surgeons than fitting traditional implants (screws and hooks). By virtue of its design, Jazz also significantly reduces the length of surgeries because it is very easy to use.

Jazz employs a technology that encircles the posterior part of the vertebra with a braid then holds it in place using a locking system that itself clips on to a rod, which fuses the vertebrae.

## Implanet has chosen NYSE Euronext Paris as a platform on which to continue expanding in general orthopaedics and roll out Jazz on a large scale

The Company is considering an IPO to give it the funds it needs to:

- continue its expansion across its entire range of orthopaedic products and especially for knee surgeries;
- maximise adoption of Jazz through an ambitious clinical programme;
- enrich the existing range of Jazz implants; and
- roll out Jazz's sales network on a large scale.



**Availability of the base document:** Implanet's *Document de base* is available at no charge upon request from Implanet (Technopole Bordeaux Montesquieu, Allée François Magendie, 33650 Martillac) and from the Company's ([www.implanet.com](http://www.implanet.com)) and the AMF's websites ([www.amf-france.org](http://www.amf-france.org)).

Registration of the base document represents the first step in Implanet's planned IPO, which is expected to go ahead subject to market conditions and the AMF's issuance of a visa on the prospectus for the transaction.

**Risk factors:** Implanet draws investors' attention to the chapter 4 "Risk factors – *Facteurs de risques*" section of the *Document de base* registered with the AMF and more particularly on the risk factor "liquidity risk – *Risque de liquidité*" presented on the section 4.7.4 of the document.

### About Implanet

Founded in 2007 and based close to Bordeaux, Implanet is a medical technology company that manufactures state-of-the-art implants for orthopaedic surgery. Jazz, its flagship product and next-generation implant, is used to improve the treatment of spinal conditions requiring vertebral fusion. Implanet's tried and tested orthopaedic platform predicated on a tight grip on the traceability of its products gives it a proven ability to reap the full benefit of this innovation. Protected by four sets of international patents, Jazz has received 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Implanet has 33 employees and posted €6.6 million in sales during 2012.

For further information, please go to [www.implanet.com](http://www.implanet.com)

### Contacts

#### Implanet

Ludovic Lastennet  
Chief Executive Officer  
Tel.: +33 (0)5 57 99 55 55  
[lt@implanet.com](mailto:lt@implanet.com)

#### NewCap.

Investor Relations & Financial Communications  
Florent Alba/Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[implanet@newcap.fr](mailto:implanet@newcap.fr)

### Disclaimer

This press release does not and shall not in any circumstances constitute a public offering nor an invitation to the public in connection with any offer of financial securities. No financial securities shall be offered to the public in France or abroad until the Autorité des marchés Financiers has granted approval (visa) of a prospectus in accordance with the provisions of Directive 2003/71/EC.

The distribution of this press release in certain countries may constitute a violation of applicable laws. The information contained in this press release does not constitute an offer of securities in the United States, Canada, Australia, Japan or

*This press release is not for publication, dissemination or distribution, directly or indirectly, in the United States, United Kingdom, Canada, Australia, Japan or Italy.*

any other country. This press release may not be published, transferred or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

This press release is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Implanet does not intend to register securities or conduct a public offering in the United States of America

*This press release is not for publication, dissemination or distribution, directly or indirectly, in the United States, United Kingdom, Canada, Australia, Japan or Italy.*